Statins and renal function

Angiology

Volumn 53, Issue 5, 2002, Pages 493-502

  Elisaf, Moses ^a   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FLUINDOSTATIN; HOMOCYSTEINE; LIPOPROTEIN A; PRAVASTATIN; SIMVASTATIN; STEROID; TACROLIMUS; THIAZIDE DIURETIC AGENT;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; GRAFT SURVIVAL; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; MICROALBUMINURIA; RISK FACTOR;

EID: 0036741488     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970205300501     Document Type: Article

References (113)

1. Elisaf M, Mikhailidis DP, Siamopoulos KC: Dyslipidemia in patients with renal diseases. J Drug Dev Clin Pract 7:331-348, 1996.
2. Attman PO, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 31:16-23, 1991.
3. Elisaf M, Dardamanis M, Pappas M, et al: Treatment of nephrotic hyperlipidemia with lovastatin. Clin Nephrol 36:50-52, 1991.
4. Rabelink AJ, Hene RJ, Erkelens DW, et al: Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet ii: 1335-1338, 1998.
5. Matthys E, Schurgers M, Lamberigts G, et al: Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients. Atherosclerosis 86:183-192, 1991.
6. Lazarus JM, Lowrie EG, Hamper CL, et al: Cardiovascular disease in uraemia and haemodialysis. Kidney Int 7:167-172, 1975.
7. Linder A, Charra B, Sherrard DJ, et al: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:690-671, 1974.
8. Keane WF, Kasiske BL, O'Donnell MP: Hyperlipidaemia and the progression of renal disease. Am J Clin Nutr 47:157-160, 1988.
9. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 33:917-924, 1988.
10. Moorhead JF: Lipids and progressive renal disease. Kidney Int 39:35-40, 1991.
11. Barcelli V, Pollack VE: Is there a role for polyunsaturated fatty acids in the prevention of renal disease and renal failure? Nephron 41:209-212, 1985.
12. Kasiske BL, O'Donnell MP, Cleary MP, et al: Treatment of hyperlipidaemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988.
13. Keane WF, Kasiske BL, O'Donnell MP: The role of lipids in progressive glomerular disease. Adv Exper Med Biol 223:81-87, 1987.
14. Miyata J, Takebayashi S: Effect of hyperlipidaemia on glomerular sclerosis in uninephrectomised rats. Acta Pathol Jpn 37:1433-1439, 1987.
15. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995.
16. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Survival Study (4S). Lancet 344:1383-1389, 1994.
17. Gaw A: Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? Atherosclerosis 125:267-269, 1996.
18. Buchwald H, Varco RL, Matts JP, et al: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidaemias (POSCH). N Engl J Med 323:946-955, 1990.
19. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes mellitus. N Engl J Med 310:356-360, 1984.
20. Bulpitt CJ, Beilin LJ, Clifton P: Risk factors for death in treated hypertensive patients. Lancet 2:134-137, 1979.
21. Tonolo G, Ciccarese M, Brizzi P, et al: Reduction of albumin excretion rate in normotensive non-insulin-dependent microalbuminuric diabetic patients during long-term Simvastatin treatment. Diabetes Care 20:1891-1895, 1997.
22. Tonolo G, Melis MG, Formato M, et al: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30:980-987, 2000.
23. Anderson TJ, Meredith IT, Yeung AC, et al: The effects of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasodilation. N Engl J Med 332:488-493, 1995.
24. Laufs U, La Fata V, Plutzky J, et al: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135, 1998.
25. Straznicky N, Howes LG, Lam W, et al: Pravastatin reduces cardiovascular reactivity to noradrenaline and angiotensin II in hypercholesterolemic hypertensives. Am J Cardiol 75:582-586, 1995.
26. Harris KPG, Purkenson ML, Yates J, et al: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 15:16-23, 1990.
27. Grandaliano G, Biswas P, Choudhury GG, et al: Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44:503-508, 1993.
28. Rabelink AJ, Hene RJ, Erkelens DW, et al: Partial remission of nephrotic syndrome in patients on long-term simvastatin. Lancet 335:1045-1046, 1990.
29. Lam KSL, Cheng IKP, Janus ED, et al: Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38:604-609, 1995.
30. Buemi M, Allegra A, Corica F, et al: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 67:427-431, 2000.
31. Nielsen S, Schimitz O, Moller N, et al: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin dependent) diabetic patients with microalbuminuria. Diabetologia 36:1079-1086, 1993.
32. Hommel E, Andersen P, Gall MA, et al: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35:447-451, 1992.
33. Giral P, Bruckert E, Jacob N, et al: Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154:421-427, 2001.
34. Marais AD, Firth JC, Bateman ME, et al: Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:1527-1531, 1997.
35. Kakafika A, Tsimihodimos V, Elisaf M: Effect of atorvastatin on serum uric acid levels. Atherosclerosis 158:255, 2001.
36. Hausberg M, Kosch M, Stam F, et al: Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 59:1473-1479, 2001.
37. Stulak JM, Lerman A, Caccitolo JA, et al: Impaired renal vascular endothelial function in vitro in experimental hypercholesterolaemia. Atherosclerosis 154:195-201, 2001.
38. Huggins GS, Pasternak RC, Alpert NM, et al: Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 98:1291-1296, 1998.
39. Kakafika A, Liamis G, Elisaf M, et al: Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17:230-231, 2001.
40. Youssef F, Seifalian AM, Jagroop A, et al: The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002; in press.
41. Davis M, Atwal AS, Nair DR, et al: The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: A pilot study. Curr Med Res Opin 16:198-204, 2000.
42. Imai Y, Suzuki H, Saito T, et al: The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and renal function research group. Clin Exper Hypertens 21:1345-1355, 1999.
43. de Lorgeril M, Salen P, Paillard F, et al: Lipid-lowering drugs and homocysteine. Lancet 353:209, 1999.
44. Landray MJ, Townend JN, Martin S, et al: Lipid-lowering drugs and homocysteine. Lancet 353: 1974-1975, 1999.
45. Dierkes J, Westphal S, Luley C: Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354:219, 1999.
46. Lüftjohann D, Sigit JI, Locatelli S, et al: High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis 155:265-266, 2001.
47. Chan NN, Chow FCC: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:1811, 2001.
48. Bostom AG: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:1811, 2001.
49. Westphal S: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:1811-12, 2001.
50. Fernandez-Miranda C, Gomez P, Diaz-Rubio P, et al: Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: Effect of treatment with folic acid. Clin Transplant 14:110-114, 2000.
51. Gale CR, Ashurst H, Phillips NJ, et al: Renal function, plasma homocysteine and carotid atherosclerosis in elderly people. Atherosclerosis 154:141-146, 2001.
52. Alcazar JM, Marin R, Gomez-Campdera F, et al: Spanish Group of Ischaemic Nephrology (GEDENI). Clinical characteristics of ischaemic renal disease. Nephrol Dial Transpl 16(suppl 1):74-77, 2001.
53. Leertouwer TC, Pattynama PM, van den Berg-Huysmans A: Incidental renal artery stenosis in peripheral vascular disease: A case for treatment? Kidney Int 59:1480-1483, 2001.
54. Rossi GP, Rossi A, Zanin L, et al: Excess prevalence of extracranial carotid artery lesions in renovascular hypertension. Am J Hypertens 5:8-15, 1992.
55. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
56. Kasiske BL: Cardiovascular disease after renal transplantation. Semin Nephrol 20:176-187, 2000.
57. Womer KL, Vella JP, Sayegh MH: Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 20:126-147, 2000.
58. Pollock CA, Mahony JF, Ong CS, et al: Hyperlipidemia in renal transplant patients: Does it matter and can we treat it. Transplant Proc 27:2152-2153, 1995.
59. Vathsala A, Weinberg RB, Schoenberg L, et al: Lipid abnormalities in cyclosporine-prednisolone treated renal transplant recipients. Transplantation 48:37-43, 1989.
60. Bumgardner GL, Wilson GA, Tso PL, et al: Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 60:1418-1421, 1995.
61. Kasiske BL, Guijarro C, Massy ZA, et al: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158-165, 1996.
62. Holdaas H, Fellstrom B, Holme I, et al: Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation): Study design and baseline data. J Cardiovasc Risk 8:63-71, 2001.
63. Kobashigawa JA, Kasiske B: Hyperlipidemia in solid organ transplantation. Transplantation 63:331-338, 1997.
64. Isoniemi H, Nurminen M, Tikkanen M, et al: Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 76:56-61, 1987.
65. Sharples L, Caine N, Mullins P, et al: Risk factors for the major hazards following heart transplantation-rejection, infection and coronary artery disease. Transplantation 52:244-252, 1991.
66. Johnson M: Transplant coronary disease: Nonimmunologic risk factors. J Heart Lung Transplant 11:124-132, 1992.
67. Kobashigawa JA, Katznelson S, Laks H, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627, 1995.
68. Wenke K, Meiser B, Thiery J, et al: Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 96:1398-1402, 1997.
69. Trimarchi HM, Brennan S, Gonzalez JM, et al: Effects of the statins in kidney transplantation. Medicina 60:457-465, 2000.
70. Kohnle M, Zimmermann U, Lutkes P, et al: Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transpl Int 13(suppl 1):S345-S348, 2000.
71. Ligtenberg G, Hene RJ, Blankestijn PJ, et al: Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 12:368-373, 2001.
72. Ichimaru N, Takahara S, Kokado Y, et al: Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine A or tacrolimus. Atherosclerosis 158:417-423, 2001.
73. Park J-W, Siekmeier R, Lattke P, et al: Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine. Am J Cardiovasc Pharmacol Therapeut 6:351-361, 2001.
74. Ohashi H, Oda H, Ohno M, et al: lipoprotein (a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int 71(suppl):S242-S244, 1999.
75. Milionis HJ, Elisaf MS, Tselepis A, et al: Apolipoprotein (a) phenotypes and lipoprotein (a) concentrations in patients with renal failure. Am J Kidney Dis 33:1100-1106, 1999.
76. Siamopoulos KC, Elisaf M, Bairaktari H, et al: Lipid parameters including Lp(a) in patients undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Perit Dial Int 15:342-347, 1995.
77. Milionis HJ, Elisaf MS, Karabina S-A, et al: Plasma and Lp(a) associated PAF-acetylhydrolase activity in uremic patients undergoing dialysis procedures. Kidney Int 56:2276-2285, 1999.
78. Malyszko J, Malyszko JS, Mysliwiec M: Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int 21:158-165, 2001.
79. Milionis HJ, Winder AF, Mikhailidis DP: Lp(a) and stroke. J Clin Pathol 53:487-496, 2000.
80. Milionis HJ, Mikhailidis DP, Winder AF: Platelets and lipoprotein (a): A brief review of their role in the pathogenesis of atherothrombosis. Platelets 10:277-284, 1999.
81. Cheshire NJW, Wolfe JHN, Barradas MA, et al: Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surgery 11:479-486, 1996.
82. Nair D, Papadakis JA, Jagroop IA, et al: Statins and fibrinogen. Lancet 351:1430, 1998.
83. Mikhailidis DP, Wierzbicki AS: HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 16:139-146, 2000.
84. Wierzbicki AS, Mikhailidis DP: Dose response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: A review of five comparative studies. Int J Cardiol 2002; in press.
85. Wierzbicki AS, Mikhailidis DP, Wray R: Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 1:327-336, 2000.
86. Jeremy JY, Mikhailidis DP, Pittilo RM: Cigarette smoking and cardiovascular disease. J R Soc Health 115:289-295, 1995.
87. Milionis HJ, Rizos E, Mikhailidis DP: Smoking diminishes the beneficial effect of statins: Observations from the landmark trials. Angiology 52:575-587, 2001.
88. Maison P, Mennen L, Sapinho D, et al: for the D.E.S.I.R. study group. A pharmacological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 160:155-160, 2002.
89. Bolton CH, Downs LG, Victory JG, et al: Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transpl 16:1189-1197, 2001.
90. Citak A, Emre S, Sairin A, et al: Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol 14:138-142, 2000.
91. Symonides B, Januszewicz A, Rowinski O, et al: Plasma fibrinogen as a risk factor for restenosis after percutaneous transluminal renal angioplasty in patients with atherosclerotic renal artery stenosis. J Cardiovasc Risk 6:269-272, 1999.
92. Goudevenos JA, Bairaktari ET, Chatzidimou KG, et al: The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia-a pilot study involving serial sampling. Curr Med Res Opin 16:269-275, 2000.
93. Wierzbicki AS, Crook MA, Nair DR, et al: More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis 148:204, 2000.
94. Ridker M, Rifai N, Clearfield M, et al: Measurement of C-reactive protein for the targeting in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001.
95. Rizos E, Kostoula A, Elisaf M, et al: Effect of ciprofibrate on CRP and fibrinogen levels. Angiology 2002; in press.
96. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002.
97. Milionis HJ, Elisaf MS, Mikhailidis DP: Platelets and lipid lowering interventions. Platelets 10:357-367, 1999.
98. Farmer JA: Pleiotropic effects of statins. Curr Atheroscler Rep 2:208-217, 2000.
99. Shlipak MG, Simon JA, Grady D, et al: Heart and Estrogen/progestin Replacement Study (HERS) investigators. J Am Coll Cardiol 38:705-711, 2001.
100. Mann JF, Gerstein HC, Pogue J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril; the HOPE randomized trial. Ann Intern Med 134:629-636, 2001.
101. Papadakis JA, Ganotakis ES, Jagroop IA, et al: Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am J Hypertension 12:673-681, 1999.
102. 1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Human Hypertens 15:203-207, 2001.
103. Jagroop IA, Mikhailidis DP: Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Human Hypertens 14:581-585, 2000.
104. Borghi C, Veronesi M, Prandin MG, et al: Statins and blood pressure regulation. Curr Hypertens Rep 3:281-288, 2001.
105. Papadakis JA, Milionis HJ, Press M, et al: Treating dyslipidaemia in non-insulin dependent diabetes mellitus-a special reference to statins. J Diabetes Complic 15:211-226, 2001.
106. Gradaus F, Ivens K, Peters AJ, et al: Angiographic progression of coronary artery disease in patients with end-stage renal disease. Nephrol Dial Transpl 16:1198-1202, 2001.
107. Vormfelde SV, Muck W, Freudenthaler SM, et al: Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance. J Clin Pharmacol 39:147-154, 1999.
108. Renders L, Mayer-Kadner I, Koch C, et al: Efficacy and drug interaction of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transpl 16:141-146, 2001.
109. Olbricht C, Wanner C, Eisenhauer, et al: Accumulation of lovastatin but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Therap 62:311-321, 1997.
110. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinetics 40:263-281, 2001.
111. Stern RH, Yang BB, Horton M, et al: Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 37:816-819, 1997.
112. Nagai T, Tomizawa T, Nkajima K, et al: Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 7:91-96, 2000.
113. Oda H, Keane WF: Recent advances in statins and the kidney. Kidney Int 71 (suppl):S2-S5, 1999.